Citations

Clear

4207 citation(s) found for "Yu, Chen".

PD‐1 is highly expressed by neoplastic B‐cells in Richter transformation
Behdad, Amir , Griffin, Brannan B. , Chen, Yi‐Hua, Ma, Shuo , Kelemen, Katalin, Lu, Xinyan , Chen, Qing C., Ma, Shuo , Chen, Yi‐Hua, Chen, Qing Ching

Mayo Clinic

British Journal of Haematology | July 20, 2018 | Volume: 185 | Issue: 2 | Pages: 370-373

10.1111/bjh.15514 | PMID 30028010 Get It

Hepatic stellate cells retain retinoid-laden lipid droplets after cellular transdifferentiation into activated myofibroblasts
Jophlin, Loretta , Koutalos, Yiannis , Chen, Chunhe, Shah, Vijay H. , Jophlin, Loretta L, Shah, Vijay H , Jophlin, Loretta L , Rockey, Don C.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | July 19, 2018 | Volume: 315 | Issue: 5 | Pages: G713-G721

10.1152/ajpgi.00251.2017 | PMID 30024770 Get It

Loss of retinyl ester (RE)-rich lipid droplets (LDs) from hepatic stellate cells (HSCs) is cited as a key event in their cellular transdifferentiation to activated, pro-fibrotic myofibroblasts; however, it remains unclear if changes in LD morphology or RE content are causal for transdifferentiation. To better understand LD dynamics in vitro within a common model of HSC activation, we used novel approaches preserving LD morphology and allowing for quantitation of RE. The size and quantity of LDs within in vitro and in vivo bile duct ligation (BDL)-activated HSCs were quantitated using adipocyte differentiation-related protein (ADRP) labeling and oil red o (ORO) staining (gold standard), and RE content was determined using fluorescence microscopy. We found during HSC activation in vitro that LD number differed significantly when measured by ADRP and ORO, respectively ( day 1: 56 vs. 5, P = 0.03; day 4: 101 vs. 39, P = 0.03; day 14: 241 vs. 12, P = 0.02). Ex vivo HSCs activated in vivo contained the same number of LDs as day 4 in vitro activated HSCs (118 vs. 101, P = 0.54). Decline in LD RE occurred beyond day 4 in vitro and day 1 ex vivo , after HSC transdifferentiation was underway. Lastly, in situ HSCs examined using electron microscopy show LDs tend to be smaller but are ultimately retained in BDL injured livers. Therefore, we conclude that during HSC transdifferentiation, LDs are not lost but are retained, decreasing in size. Additionally, RE content declines after transdifferentiation is underway. These data suggest that these LD changes are not causal for HSC transdifferentiation.NEW & NOTEWORTHY Loss of retinoid-laden lipid droplets from hepatic stellate cells has long been held as a hallmark of their transdifferentiation into activated myofibroblasts, the dominant cells that drive hepatic fibrosis. This study demonstrates that stellate cells activated in culture and after liver injury in vivo retain their lipid droplets and that these droplets become smaller and more numerous, with decreases in droplet retinoid concentration occurring only after cellular transdifferentiation is underway.
Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure
Chen, Harvey S., Joo, Dong Jin , Shaheen, Mohammed F. , Li, Yi , Wang, Yujia , Nicolas, Clara T., Predmore, Kelly, Amiot, Bruce , Michalak, Gregory, Mounajjed, Taofic, Fidler, Jeff L. , Kremers, Walter K. , Nyberg, Scott L. , Shaheen, Mohammed, Fidler, Jeff, Kremers, Walter K , Yang, Jian , Predmore, Kelly S, Fidler, Jeff L.

Mayo Clinic

Hepatology | July 19, 2018 | Volume: 69 | Issue: 1 | Pages: 329-342

10.1002/hep.30184 | PMID 30022502 Get It

Acute liver failure (ALF) is a catastrophic condition that can occur after major liver resection. The aim of this study was to determine the effects of the spheroid reservoir bio‐artificial liver (SRBAL) on survival, serum chemistry, and liver regeneration in posthepatectomy ALF pigs. Wild‐type large white swine (20 kg‐30 kg) underwent intracranial pressure (ICP) probe placement followed by 85% hepatectomy. Computed tomography (CT) volumetrics were performed to measure the extent of resection, and at 48 hours following hepatectomy to assess regeneration of the remnant liver. Animals were randomized into three groups based on treatment delivered 24‐48 hours after hepatectomy: Group1—standard medical therapy (SMT, n = 6); Group2—SMT plus bio‐artificial liver treatment using no hepatocytes (0 g, n = 6); and Group3—SMT plus SRBAL treatment using 200 g of primary porcine hepatocyte spheroids (200 g, n = 6). The primary endpoint was survival to 90 hours following hepatectomy. Death equivalent was defined as unresponsive grade 4 hepatic encephalopathy or ICP greater than 20 mmHg with clinical evidence of brain herniation. All animals in both (SMT and 0 g) control groups met the death equivalent before 51 hours following hepatectomy. Five of 6 animals in the 200‐g group survived to 90 hours ( P < 0.01). The mean ammonia, ICP, and international normalized ratio values were significantly lower in the 200‐g group. CT volumetrics demonstrated increased volume regeneration at 48 hours following hepatectomy in the 200‐g group compared with the SMT ( P < 0.01) and 0‐g (P < 0.01) groups. Ki‐67 staining showed increased positive staining at 48 hours following hepatectomy ( P < 0.01). Conclusion: The SRBAL improved survival, reduced ammonia, and accelerated liver regeneration in posthepatectomy ALF. Improved survival was associated with a neuroprotective benefit of SRBAL therapy. These favorable results warrant further clinical testing of the SRBAL.
End of Life, Withdrawal, and Palliative Care Utilization among Patients Receiving Maintenance Hemodialysis Therapy
Chen, Joy Chieh-Yu, Vaughan, Lisa E. , Feely, Molly A., Albright, Robert C. , Norby, Suzanne M. , Gossett, Christy, d’Uscio, Margaret, Williams, Amy W. , Hickson, LaTonya J. , Onuigbo, Macaulay , Norby, Suzanne M , Hickson, LaTonya J , Chen, Joy Chieh-Yu, Thorsteinsdottir, Bjorg , Dillon, John

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 19, 2018 | Volume: 13 | Issue: 8 | Pages: 1172-1179

10.2215/cjn.00590118 | PMID 30026285 Get It

Background and objectives Withdrawal from maintenance hemodialysis before death has become more common because of high disease and treatment burden. The study objective was to identify patient factors and examine the terminal course associated with hemodialysis withdrawal, and assess patterns of palliative care involvement before death among patients on maintenance hemodialysis. Design, setting, participants, & measurements We designed an observational cohort study of adult patients on incident hemodialysis in a midwestern United States tertiary center, from January 2001 to November 2013, with death events through to November 2015. Logistic regression models evaluated associations between patient characteristics and withdrawal status and palliative care service utilization. Results Among 1226 patients, 536 died and 262 (49% of 536) withdrew. A random sample (10%; 52 out of 536) review of Death Notification Forms revealed 73% sensitivity for withdrawal. Risk factors for withdrawal before death included older age, white race, palliative care consultation within 6 months, hospitalization within 30 days, cerebrovascular disease, and no coronary artery disease. Most withdrawal decisions were made by patients (60%) or a family member (33%; surrogates). The majority withdrew either because of acute medical complications (51%) or failure to thrive/frailty (22%). After withdrawal, median time to death was 7 days (interquartile range, 4–11). In-hospital deaths were less common in the withdrawal group (34% versus 46% nonwithdrawal, P =0.003). A third (34%; 90 out of 262) of those that withdrew received palliative care services. Palliative care consultation in the withdrawal group was associated with longer hemodialysis duration (odds ratio, 1.19 per year; 95% confidence interval, 1.10 to 1.3; P <0.001), hospitalization within 30 days of death (odds ratio, 5.78; 95% confidence interval, 2.62 to 12.73; P <0.001), and death in hospital (odds ratio, 1.92; 95% confidence interval, 1.13 to 3.27; P =0.02). Conclusions In this single-center study, the rate of hemodialysis withdrawals were twice the frequency previously described. Acute medical complications and frailty appeared to be driving factors. However, palliative care services were used in only a minority of patients.
Diagnosis, assessment, and management of surgical complications following esophagectomy
Grimminger, Peter , Bergeat, Damien , Bertheuil, Nicolas , Chandramohan, Servarayan Murugesan, Chen, Ke‐Neng , Chon, Seung‐Hun , Collet, Denis, Goh, Khean‐Lee, Gronnier, Caroline , Liu, J F, Nafteux, P., Pirchi, Enrique D, Schiesser, Marc , Wu, Aaron , Wu, Peter , Buttar, Navtej , Chang, Andrew C. , Grimminger, Peter P , Chang, Andrew C , Goense, Lucas , Gockel, Ines , Meunier, Bernard , Thieme, René

Mayo Clinic

Annals of the New York Academy of Sciences | July 9, 2018 | Volume: 1434 | Issue: 1 | Pages: 254-273

10.1111/nyas.13920 | PMID 29984413 Get It

AbstractDespite improvements in operative strategies for esophageal resection, anastomotic leaks, fistula, postoperative pulmonary complications, and chylothorax can occur. Our review seeks to identify potential risk factors, modalities for early diagnosis, and novel interventions that may ameliorate the potential adverse effects of these surgical complications following esophagectomy.
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial
Solomon, Scott D. , Rizkala, Adel R. , Lefkowitz, Martin, Shi, Victor , Gong, Jianjian , Anavekar, Nagesh S., Arango, Juan Luis, Arenas, J., Ben-Gal, T., Boytsov, S. А. , Chen, Chen-Huan, Cleland, John G.F. , DUENGEN, H, Echeverría, Luis Eduardo , Filippatos, Gerasimos , Flammer, Andreas J. , Galinier, Michel , Godoy, Armando, Gonçalvesová, Eva , Janssens, Stefan , Katova, Tzvetana, Køber, Lars , Lelonek, Małgorzata , Linssen, Gerard C.M. , Lund, Lars H. , O’Meara, Eileen , Perrone, Sergio V. , Ranjith, Naresh , Saito, Yoshihiko , Saraiva, Jose F. Kerr, Shah, Sanjiv J. , Seferović, Petar , Sibulo, Antonio S., Sim, David , Sweitzer, Nancy K. , Taurio, Jyrki , Vinereanu, Dragoş , Vrtovec, Bojan , Yılmaz, Mehmet Birhan , Zhou, Jingmin , Zweiker, Robert , Anand, Inder S. , Maggioni, Aldo P. , Pieske, Burkert , Redfield, Margaret M. , Rouleau, Jean L. , Veldhuisen, Dirk J. van , Zannad, Faı̈ez , Zile, Michael R. , McMurray, John J.V. , Felker, G. Michael , Zile, Michael R , Anand, Inder S , Maggioni, Aldo P , McMurray, John J V , Shah, Sanjiv J , Solomon, Scott David , Anker, Stefan D. , Atar, Dan , Chopra, Vijay , Comín‐Colet, Josep , Merkely, Béla , Miličić, Davor , Oh, Byung‐Hee , Senni, Michele , Sim, David , Jr., Jiri Widimsky , Ge, Junbo , Lam, Carolyn S.P. , Martínez‐Pastor, Felipe , Packer, Milton , Pfeffer, Marc Alan , Køber, Lars , Cleland, John G F

Mayo Clinic

Circulation: Heart Failure | July 6, 2018 | Volume: 11 | Issue: 7 | Pages: No page available

10.1161/circheartfailure.118.004962 | PMID 29980595 Get It

Background: To describe the baseline characteristics of patients with heart failure and preserved left ventricular ejection fraction enrolled in the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF) comparing sacubitril/valsartan to valsartan in reducing morbidity and mortality. Methods and Results: We report key demographic, clinical, and laboratory findings, and baseline therapies, of 4822 patients randomized in PARAGON-HF, grouped by factors that influence criteria for study inclusion. We further compared baseline characteristics of patients enrolled in PARAGON-HF with those patients enrolled in other recent trials of heart failure with preserved ejection fraction (HFpEF). Among patients enrolled from various regions (16% Asia-Pacific, 37% Central Europe, 7% Latin America, 12% North America, 28% Western Europe), the mean age of patients enrolled in PARAGON-HF was 72.7±8.4 years, 52% of patients were female, and mean left ventricular ejection fraction was 57.5%, similar to other trials of HFpEF. Most patients were in New York Heart Association class II, and 38% had ≥1 hospitalizations for heart failure within the previous 9 months. Diabetes mellitus (43%) and chronic kidney disease (47%) were more prevalent than in previous trials of HFpEF. Many patients were prescribed angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (85%), β-blockers (80%), calcium channel blockers (36%), and mineralocorticoid receptor antagonists (24%). As specified in the protocol, virtually all patients were on diuretics, had elevated plasma concentrations of N-terminal pro-B-type natriuretic peptide (median, 911 pg/mL; interquartile range, 464–1610), and structural heart disease. Conclusions: PARAGON-HF represents a contemporary group of patients with HFpEF with similar age and sex distribution compared with prior HFpEF trials but higher prevalence of comorbidities. These findings provide insights into the impact of inclusion criteria on, and regional variation in, HFpEF patient characteristics. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01920711.
Reply to comment on: Ileocecal vascularized lymph node transfer for the treatment of extremity lymphedema: A case report
Ciudad, Pedro , Manrique, Oscar J. , Agko, Mouchammed , Huang, Chieh‐Ting, Chang, Wei‐Ling , B, Ricardo Delgado, Reynaga, César, Saçak, Bülent , Mouchammed, Agko , Chen, Hung‐Chi

Mayo Clinic

Microsurgery | July 5, 2018 | Volume: 38 | Issue: 6 | Pages: 723-724

10.1002/micr.30336 | PMID 29974502 Get It

Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma
Li, Qian , Hou, Xiaonan , Weroha, S. John , Kalli, Kimberly R., Cunningham, Julie M. , Lawrenson, Kate , Gayther, Simon A. , Goode, Ellen L. , Cunningham, Julie M , Lawrenson, Kate , Fridley, Brooke L. , Dai, Junqiang , Raghavan, Rama , Winham, Stacey J. , Wang, Chen

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 2, 2018 | Volume: 27 | Issue: 9 | Pages: 1101-1109

10.1158/1055-9965.epi-17-0728 | PMID 29967001 Get It

Abstract Background: Endometrioid carcinoma (EC) and clear cell carcinoma (CC) histotypes of epithelial ovarian cancer are understudied compared with the more common high-grade serous carcinomas (HGSC). We therefore sought to characterize EC and CC transcriptomes in relation to HGSC. Methods: Following bioinformatics processing and gene abundance normalization, differential expression analysis of RNA sequence data collected on fresh-frozen tumors was completed with nonparametric statistical analysis methods (55 ECs, 19 CCs, 112 HGSCs). Association of gene expression with progression-free survival (PFS) was completed with Cox proportional hazards models. Eight additional multi-histotype expression array datasets (N = 852 patients) were used for replication. Results: In the discovery set, tumors generally clustered together by histotype. Thirty-two protein-coding genes were differentially expressed across histotype (P &lt; 1 × 10−10) and showed similar associations in replication datasets, including MAP2K6, KIAA1324, CDH1, ENTPD5, LAMB1, and DRAM1. Nine genes associated with PFS (P &lt; 0.0001) showed similar associations in replication datasets. In particular, we observed shorter PFS time for CC and EC patients with high gene expression for CCNB2, CORO2A, CSNK1G1, FRMD8, LIN54, LINC00664, PDK1, and PEX6, whereas, the converse was observed for HGSC patients. Conclusions: The results suggest important histotype differences that may aid in the development of treatment options, particularly those for patients with EC or CC. Impact: We present replicated findings on transcriptomic differences and how they relate to clinical outcome for two of the rarer ovarian cancer histotypes of EC and CC, along with comparison with the common histotype of HGSC. Cancer Epidemiol Biomarkers Prev; 27(9); 1101–9. ©2018 AACR.
A Middle-aged Woman With Vision Loss and Cecocentral Scotoma
Jacobi, Jaclyn E., Leavitt, Jacqueline A., Chen, John J. , Chen, John J

Mayo Clinic

JAMA Ophthalmology | June 28, 2018 | Volume: 136 | Issue: 9 | Pages: 1070

10.1001/jamaophthalmol.2018.0077 | PMID 29955763 Get It